- Joined
- Nov 5, 2009
- Messages
- 14,212
- Reason
- Lost a loved one
- Diagnosis
- 00/0000
- Country
- US
- State
- WA
- City
- Seattle
The trial showed delayed progression, which is not quite the same thing as improved survival. Remember, most people with ALS don't just suddenly die. Gradually their condition often goes to a point where continued survival isn't seen as the best thing. That's when people typically die.
So a trial that shows slower progression suggests that PALS who use the compound might take longer to reach that point, but it's also possible it might stop working as well or at all, that earlier cases might actually see less benefit, etc. We don't yet know those things. And the scale used to determine the progression rate (ALSFRS-R) is very flawed, so in longer use, AMX might do more or less than the trial suggested.
For now, we can say is that it did enough in terms of slowing progression for the Canadian authorities to allow Amylyx to submit an application for approval.
So a trial that shows slower progression suggests that PALS who use the compound might take longer to reach that point, but it's also possible it might stop working as well or at all, that earlier cases might actually see less benefit, etc. We don't yet know those things. And the scale used to determine the progression rate (ALSFRS-R) is very flawed, so in longer use, AMX might do more or less than the trial suggested.
For now, we can say is that it did enough in terms of slowing progression for the Canadian authorities to allow Amylyx to submit an application for approval.